Table 2.

Safety and adverse events of special interest by baseline KDIGO risk categories and subgroups of UACR and eGFR

	n/N		OR (95% CI)	p for interaction
	Dapagliflozin	Placebo
Discontinuation due to adverse event
Overall	118/2149	123/2149	0.97 (0.74, 1.26)
KDIGO risk category
Moderately high risk	8/330	12/289	0.56 (0.22, 1.38)	0.41
High risk	31/651	32/696	1.03 (0.62, 1.71)
Very high risk	79/1168	79/1164	1.03 (0.74, 1.42)
UACR subgroup
UACR ≤113.0	55/1102	50/1119	1.12 (0.76, 1.66)	0.48
UACR >113.0 to ≤395.5	47/881	54/882	0.87 (0.58, 1.30)
UACR >395.5	16/166	19/148	0.71 (0.35, 1.46)
eGFR subgroup
eGFR ≥45	30/879	42/901	0.73 (0.45, 1.19)	0.20
eGFR ≥30 to <45	60/977	45/917	1.26 (0.84, 1.87)
eGFR <30	28/293	36/331	0.84 (0.50, 1.43)
Any serious adverse event
Overall	633/2149	729/2149	0.81 (0.72, 0.93)
KDIGO risk category
Moderately high risk	89/330	106/289	0.64 (0.45, 0.90)	0.26
High risk	176/651	205/696	0.89 (0.70, 1.12)
Very high risk	368/1168	418/1164	0.83 (0.70, 0.98)
UACR subgroup
UACR ≤113.0	284/1102	344/1119	0.78 (0.65, 0.95)	0.79
UACR >113.0 to ≤395.5	279/881	313/882	0.85 (0.69, 1.03)
UACR >395.5	70/166	72/148	0.77 (0.49, 1.22)
eGFR subgroup
eGFR ≥45	237/879	289/901	0.78 (0.63, 0.96)	0.54
eGFR ≥30 to <45	295/977	302/917	0.88 (0.72, 1.07)
eGFR <30	101/293	138/331	0.72 (0.52, 1.00)

Data are based on the safety population of 4298

Cut-off values for UACR are mg/mmol (in mg/g: ≤1000 mg/g, >1000 to ≤3500 mg/g, >3500 mg/g); cut-off values for eGFR are ml min⁻¹ [1.73 m]⁻²